AICAR (Acadesine)
别名: NSC105823, AICA Riboside
中文名称:阿卡地新
目录号:S1802 Purity: 99.97%
AICAR (Acadesine, NSC105823, AICA Riboside)是AMPK的激活剂,引起ZMP积累,模拟AMP对AMPK和AMPKK的刺激作用。AICAR (Acadesine)可诱导线粒体自噬。Phase 3。
CAS: 2627-69-2
客户使用Selleck的AICAR (Acadesine)发表文献156篇
- Cell Res, 2023 33(11):821-834
- Cell Stem Cell, 2023 30(8):1028-1042.e7
- Mil Med Res, 2023 10(1):64
- Signal Transduct Target Ther, 2022 7(1):66
- Cell Res, 2021 10.1038/s41422-021-00565-y
- J Clin Invest, 2024 134(22)e181314
- J Clin Invest, 2024 e175023
- Research (Wash D C), 2024 7:0400
- J Cachexia Sarcopenia Muscle, 2024 15(5):1733-1749
- Elife, 2024 12RP87518
- J Transl Med, 2024 22(1):844
- Cell Death Discov, 2024 10(1):95
- Cancers (Basel), 2024 16(5)976
- Cell Signal, 2024 117:111080
- FEBS Open Bio, 2024 10.1002/2211-5463.13872
- Clin Transl Med, 2023 13(9):e1369
- Cell Death Dis, 2023 14(7):469
- Br J Cancer, 2023 10.1038/s41416-023-02196-z
- Biomed Pharmacother, 2023 161:114412
- J Orthop Translat, 2023 38:158-166
- Antioxid Redox Signal, 2023 39(1-3):166-185.
- mBio, 2023 e0061123.
- iScience, 2023 26(3):106193
- Int J Mol Sci, 2023 24(4)3823
- Int J Mol Med, 2023 52(1)56
- Poult Sci, 2023 102(2):102385
- Heliyon, 2023 9(11):e22093
- Acta Biochim Biophys Sin (Shanghai), 2023 55(3):460-471
- bioRxiv, 2023 10.1101/2023.03.29.534670
- Research Square, 2023 10.21203/rs.3.rs-3680631/v1
- bioRxiv, 2023 2023.03.29.534670
- Nat Commun, 2022 13(1):7335
- Nat Commun, 2022 13(1):7031
- Acta Pharm Sin B, 2022 12(2):651-664
- Cell Death Dis, 2022 13(11):976
- Cell Prolif, 2022 e13358.
- Aging Dis, 2022 13(2):552-567
- Oxid Med Cell Longev, 2022 2022:8332825
- Cell Mol Gastroenterol Hepatol, 2022 S2352-345X(22)00168-0
- J Agric Food Chem, 2022 70(32):9898-9907
- Food Funct, 2022 13(10):5870-5882
- Food Funct, 2022 10.1039/d1fo03752h
- Life Sci, 2022 303:120676
- Cells, 2022 11(15)2429
- Front Cell Infect Microbiol, 2022 12:804011
- Int J Mol Sci, 2022 23(2415508)
- Int J Mol Sci, 2022 23(22)13703
- Int J Mol Sci, 2022 23(17)10042
- Mar Drugs, 2022 20(6)378
- Front Endocrinol (Lausanne), 2022 13:895360
- Front Endocrinol (Lausanne), 2022 13:1081039
- Front Nutr, 2022 9:917801
- Front Nutr, 2022 9:849684
- Front Physiol, 2022 13:974825
- Sci Adv, 2022 8(28):eabo3064
- Bull Exp Biol Med, 2022 173(3):366-370
- Cell Insight, 2022 1(4):100045
- Nat Commun, 2021 12(1):5058
- Oxid Med Cell Longev, 2021 2021:7467156
- Oxid Med Cell Longev, 2021 2021:8996482
- J Invest Dermatol, 2021 S0022-202X(21)02466-0
- iScience, 2021 24(9):103038
- Mol Med, 2021 27(1):156
- Int J Mol Sci, 2021 22(22)12341
- J Cell Physiol, 2021 10.1002/jcp.30319
- Cancer Biol Med, 2021 j.issn.2095-3941.2020.0262
- Front Cell Dev Biol, 2021 9:644667
- Front Cell Dev Biol, 2021 9:722024
- J Virol, 2021 JVI0155021
- Mol Cell Biol, 2021 MCB0032721
- Aging (Albany NY), 2021 13(17):21251-21267
- J Biol Chem, 2021 S0021-9258(21)00215-5
- J Cell Sci, 2021 134(24)jcs259306
- Cell Stress Chaperones, 2021 10.1007/s12192-021-01201-9
- Front Cardiovasc Med, 2021 8:757591
- Genes (Basel), 2021 12(1)E119
- Exp Eye Res, 2021 213:108854
- Biotechnol Lett, 2021 10.1007/s10529-021-03112-2
- Curr Eye Res, 2021 1-10
- Sci Adv, 2021 7(35)eabj0364
- Nat Commun, 2020 11(1):3321
- J Clin Invest, 2020 130(8):4006-4018
- Cell Death Dis, 2020 8;11(6):427
- Cell Death Dis, 2020 11(7):607
- J Dent Res, 2020 22034520935788
- Cell Biosci, 2020 20;10:43
- Oxid Med Cell Longev, 2020 2020:6104375
- J Agric Food Chem, 2020 68(40):11229-11241
- Mol Ther Oncolytics, 2020 18:282-294
- Front Pharmacol, 2020 11:587176
- Front Cell Dev Biol, 2020 8:575903
- J Biol Chem, 2020 jbc.RA120.13703
- FASEB J, 2020 10.1096/fj.202001168RR
- Biosci Rep, 2020 40(6):BSR20194389
- Cell Microbiol, 2020 22(2):e13131
- Circ J, 2020 84(2):217-225
- Eur Rev Med Pharmacol Sci, 2020 24(2):905-914
- Cell Biochem Biophys, 2020 10.1007/s12013-020-00952-z
- J Exp Clin Cancer Res, 2019 38(1):192
- Cell Death Dis, 2019 10(9):627
- Cell Rep, 2019 27(12):3413-3421
- Biomed Pharmacother, 2019 113:108558
- Oxid Med Cell Longev, 2019 2019:7189854
- Br J Pharmacol, 2019 176(16):2877-2893
- Br J Pharmacol, 2019 176(20):3983-4001
- Phytother Res, 2019 10.1002/ptr.6368
- Antioxid Redox Signal, 2019 30(2):163-183
- Biochim Biophys Acta Mol Basis Dis, 2019 1865(6):1701-1712
- Life Sci, 2019 224:197-203
- Life Sci, 2019 239:116877
- J Cell Physiol, 2019 10.1002/jcp.29307
- Eur J Pharmacol, 2019 854:328-337
- Sci Rep, 2019 9(1):1897
- Molecules, 2019 24(19)
- Biochem Biophys Res Commun, 2019 508(3):701-708
- Oncol Res, 2019 10.3727/096504019X15518706875814
- Int J Hyperthermia, 2019 36(1):499-510
- Am J Transl Res, 2019 11(3):1498-1509
- Methods Mol Biol, 2019 1880:429-445
- J Clin Invest, 2018 10.1172/JCI122064
- Biomed Pharmacother, 2018 107:785-792
- Aging Dis, 2018 9(1):66-76
- Front Immunol, 2018 9:1714
- Nanoscale, 2018 10(3):1494-1507
- Mol Oncol, 2018 10.1002/1878-0261.12403
- J Cell Mol Med, 2018 22(3):1583-1600
- Sci Rep, 2018 8(1):6028
- Sci Rep, 2018 8(1):9204
- World J Gastroenterol, 2018 24(7):819-832
- Biosci Rep, 2018 38(6)
- Biochem Biophys Res Commun, 2018 497(2):564-570
- Biochem Biophys Res Commun, 2018 500(3):710-716
- Biochem Biophys Res Commun, 2018 505(4):1195-1202
- Exp Ther Med, 2018 15(1):864-872
- Nat Commun, 2017 8:15637
- Cell Biosci, 2017 7:43
- Antioxid Redox Signal, 2017 27(5):251-268
- Oncotarget, 2017 8(40):67942-67954
- Oncotarget, 2017 8(61):103985-103995
- Neuropharmacology, 2017 125:408-417
- Sci Rep, 2017 7:46751
- Sci Rep, 2017 7:41606
- Mol Carcinog, 2017 56(5):1427-1437
- Cell Physiol Biochem, 2017 44(5):1965-1979
- J Cancer, 2017 8(18):3675-3681
- PLoS One, 2017 12(1):e0170409
- J Appl Toxicol, 2017 10.1002/jat.3483
- Biochem Biophys Res Commun, 2017 486(2):398-405
- J Ethnopharmacol, 2016 193:691-699
- Am J Physiol Endocrinol Metab, 2016 310(3):E225-37
- Sci Rep, 2016 6:30272
- PLoS One, 2016 11(1):e0147230
- Br J Pharmacol, 2015 10.1111/bph.13120
- Apoptosis, 2015 20(10):1373-87
- J Mol Cell Cardiol, 2015 85:155-67
- Br J Cancer, 2014 111(8):1562-71
化学信息&溶解度
分子量 | 258.23 |
分子式 | C9H14N4O5 |
CAS号 | 2627-69-2 |
Smiles | C1=NC(=C(N1C2C(C(C(O2)CO)O)O)N)C(=O)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 51 mg/mL ( 197.49 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 20 mg/mL Ethanol : Insoluble DMSO : 52 mg/mL ( 201.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 52 mg/mL Ethanol : Insoluble DMSO : 51 mg/mL ( 197.49 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 52 mg/mL ( 201.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 26 mg/mL Ethanol : Insoluble DMSO : 52 mg/mL ( 201.37 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 20 mg/mL Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
10%DMSO
40%PEG300
5%Tween80
45%ddH2O
浓度:30mg/ml
(116.18mM)
操作示例:以 1 mL 工作液为例,取100 μL 300mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入450 μL ddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。